Jodi Rose, NP
Family · Cleveland, TNNPI 1124494513
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $34,514 of the $56,987 with a category attached, or 60.6%. 60 manufacturers reported payments, led by Biohaven Pharmaceutical Holding Company Ltd. at 35.4% of the total. Reporting peaked in 2022 at $21,629 and has fallen 77.8% since, to $4,808 in 2025. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,140 payments — averaging $49.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biohaven Pharmaceutical Holding Company Ltd.$20K
- Biohaven Pharmaceuticals, Inc.$18K
- AbbVie$2K
- UCB, Inc.$2K
- Livanova USA, Inc.$1K
- Acadia Pharmaceuticals Inc$916
- plus $12K from 54 others
What the payments were for
- Speaking & faculty fees$34,51461%
- Travel & lodging$2,2214%
- Food & beverage$20,13935%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$36,513
- VNS Therapy$1,291
- NUPLAZID$235
- Senza$141
- Fycompa$120
- VYEPTI$118
- Briviact$112
- Fintepla$108
- ULTOMIRIS$102
How this compares
$56,987 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 102 | $173,688 |
| IngrezzaValbenazine Tosylate | 11 | $93,949 |
| NuplazidPimavanserin Tartrate | 20 | $87,945 |
| Emgality PenGalcanezumab-Gnlm | 106 | $85,590 |
| UbrelvyUbrogepant | 34 | $44,176 |
| QuliptaAtogepant | 23 | $26,635 |
| AptiomEslicarbazepine Acetate | 13 | $23,811 |
| Aimovig AutoinjectorErenumab-Aooe | 23 | $21,451 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 22 | $20,382 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $19,458 |
| XcopriCenobamate | 14 | $19,145 |
| Lacosamide | 82 | $13,463 |
| Levetiracetam | 164 | $5,542 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 142 | $5,239 |
| Primidone | 129 | $4,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $646 | $173,688102 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $676 | $93,94911 claims |
| Acadia Pharmaceuticals IncNuplazid | $916 | $87,94520 claims |
| AbbVieUbrelvy, Qulipta | $2,232 | $70,81157 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $213 | $23,81113 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $94 | $19,45812 claims |
| SK Life Science, Inc.Xcopri | $374 | $19,14514 claims |
| Upsher-smith Laboratories LLCTopiramate | $142 | $46041 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Cleveland
- Jateum BlackburnCleveland$143K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.